September 27th 2023
Ocuphire Pharma and Viatris developed the drug together for the reversal of pharmacologically-induced mydriasis (RM) produced by adrenergic agonist or parasympatholytic agents.
September 27th 2023
Enjoy these CME sessions at AAO 2023
Register Now!
C.R.U. Eye Symposium (Current, Relevant, Useful)
11/10/2023-11/12/2023
Register Now!
The Ophthalmology Times EyeCon 2023
Register Now!
Free COPE CE at AAOPT
Register Now!
Clinical Consultations: Individualizing Management of Uveitic Macular Edema - Clinical Updates in Treatment Options
View More
Community Practice Connections™: Ophthalmology and Oncology Perspectives on Integrating Novel Bispecific Antibodies Into the Uveal Melanoma Treatment Paradigm
View More
Medical Crossfire®: Ophthalmology and Oncology Perspectives on Integrating Novel Bispecific Antibodies Into the Uveal Melanoma Treatment Paradigm
View More
The Optometry Times EyeCon 2023
Register Now!
(CME Credit) Community Practice Connections™: Expert Approaches in Cataract Surgery – Managing Advances in Techniques and Technologies With an Updated Armamentarium
View More
(COPE Credit) Community Practice Connections™: Expert Approaches in Cataract Surgery – Managing Advances in Techniques and Technologies With an Updated Armamentarium
View More
(CME/CNE Credit) MGD-Associated Dry Eye Disease – How Emerging Options May Shift the Treatment Paradigm
View More
(COPE Credit) MGD-Associated Dry Eye Disease – How Emerging Options May Shift the Treatment Paradigm
View More
(CME/CNE Credit) Expert Illustrations & Commentaries™: Envisioning New Therapies for Meibomian Gland Dysfunction-Associated DED
View More
(COPE Credit) Expert Illustrations & Commentaries™: Envisioning New Therapies for Meibomian Gland Dysfunction-Associated DED
View More
(COPE Credit) Patient, Provider, and Caregiver Connection™: Individualizing Care in Allergic Conjunctivitis – Understanding the Patient’s Perspective in Alleviating Disease Burden
View More
(CME Credit) Patient, Provider, and Caregiver Connection™: Individualizing Care in Allergic Conjunctivitis – Understanding the Patient’s Perspective in Alleviating Disease Burden
View More
Perfecting Co-Management of Glaucoma – Utilizing Development in the Spectrum of Treatment Options
View More
Shared Perspectives in Managing Presbyopia – Understanding a New Paradigm for Optimizing Quality of Life
View More
Expert Insights in Geographic Atrophy with Transformative Care on the Horizon – Understanding the Complement System as a Target for Treatment
View More
Community Practice Connections™: 2nd Annual Optometry Times™ EyeCon
View More
Community Practice Connections™: Ophthalmology Times® EyeCon 2022
View More
Medical Crossfire®: Expert Perspectives in Geographic Atrophy – How Can We Prepare for a New Era of Treatment?
View More
(CME Credit) Addressing Healthcare Inequities Diabetic Retinal Vascular Disease: How Can We Address Ethnic Disparities within the Clinic?
View More
(COPE Credit) Addressing Healthcare Inequities Diabetic Retinal Vascular Disease: How Can We Address Ethnic Disparities within the Clinic?
View More
(CME/CNE Credit) Analyzing Novel Tear Stimulating Treatments for Special Populations in Dry Eye Disease
View More
(CME Credit) Community Practice Connection™: Paradigm Shifts in Presbyopia – Understanding Advances in Topical Treatment Innovations
View More
(COPE Credit) Analyzing Novel Tear Stimulating Treatments for Special Populations in Dry Eye Disease
View More
(COPE Credit) Community Practice Connections™: Improving Management of MGD-Associated Dry Eye Disease—A Look to the Future of Treatment
View More
(COPE Credit) Community Practice Connections™: Restoring the Surface – Impact of Preservatives and Novel Formulations in First Line Treatments for Dry Eye Disease
View More
(CME Credit) Community Practice Connections™: Improving Management of MGD-Associated Dry Eye Disease—A Look to the Future of Treatment
View More
Study: Scientists develop new therapeutic model for potentially treating incurable eye diseases
August 24th 2023A team of researchers have successfully transplanted human microglia into a mouse retina to create a model for studying eye disease treatments, such as diabetic retinopathy, glaucoma and age-related macular degeneration.
Read More
FDA approves aflibercept injection 8mg for treatment of wet AMD, DME, DR
August 19th 2023According to Regeneron, the approval was based on data in the PULSAR and PHOTON trials, in which the drug demonstrated clinically equivalent vision gains to aflibercept Injection 2 mg that were maintained with fewer injections.
Read More
ASRS Live: Regeneron presents aflibercept 8 mg two-year results from PHOTON trial in DME
July 30th 2023In a presentation at the American Society of Retina Specialists 41st Annual Meeting in Seattle, Diana Do, MD, said the PHOTON study demonstrated the impact aflibercept 8 mg could have in reducing the treatment burden for patients diagnosed with DME.
Read More
Dry eye paradise: FDA green-lights Miebo as first and only eye drop approved for the condition
June 21st 2023Experts in the field weigh in on the perfluorohexyloctane ophthalmic solution, the first and only FDA-approved treatment for DED that directly targets tear evaporation instead of tear formation.
Read More